ethyl 2-(2-propynyloxy)propionate | 134126-58-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(2-propynyloxy)propionate
• 英文别名: 2-(2-propynyloxy)propanoic acid ethyl ester；Ethyl 2-(prop-2-ynyloxy)propanoate；ethyl 2-prop-2-ynoxypropanoate
• CAS: 134126-58-2
• 化学式: C₈H₁₂O₃
• 分子量: 156.181
• InChiKey: MOLGNILWRIAKFZ-UHFFFAOYSA-N

物化性质

• 沸点：
  80-82 °C(Press: 4 Torr)
• 密度：
  1.0373 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(2-propynyloxy)propionate 在 硫酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以74%的产率得到2-(2-丙炔-1-氧基)丙酸
  参考文献：
  名称：

  Yamamoto, Makoto; Dewa, Toshikazu; Munakata, Hiroshi, Journal of Chemical Research, Miniprint, 1991, # 7, p. 1771 - 1782

  摘要：

  DOI：
• 作为产物：
  描述：

  乳酸乙酯 、 3-溴丙炔 在 sodium hydride 作用下， 生成 ethyl 2-(2-propynyloxy)propionate
  参考文献：
  名称：

  Yamamoto, Makoto; Dewa, Toshikazu; Munakata, Hiroshi, Journal of Chemical Research, Miniprint, 1991, # 7, p. 1771 - 1782

  摘要：

  DOI：

文献信息

• Indole Compounds, Method of Preparing Them and Uses Thereof
  申请人：BINET Jean

  公开号：US20080153816A1

  公开（公告）日：2008-06-26

  Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.

  与公式（I）相对应的吲哚化合物，如权利要求中所定义的，这些化合物的药学上可接受的加盐物，含有这些化合物的药物组合物，其制备方法，以及它们作为药理活性物质的用途，特别是在治疗高三酰甘油血症、高脂血症、高胆固醇血症、糖尿病、内皮功能障碍、心血管疾病、炎症性疾病和神经退行性疾病方面。
• Stephen; Hashmi; Schwarz, Lothar, Chemische Berichte, 1997, vol. 130, # 10, p. 1449 - 1456
  作者：Stephen、Hashmi、Schwarz, Lothar

  DOI：——

  日期：——
• AKOPYAN, S. M.;ZALINYAN, M. G., ARM. XIM. ZH., 43,(1990) N0, S. 664-668
  作者：AKOPYAN, S. M.、ZALINYAN, M. G.

  DOI：——

  日期：——
• BIODEGRADABLE DRUG-POLYMER CONJUGATE
  申请人：POLYACTIVA PTY LTD

  公开号：US20200123322A1

  公开（公告）日：2020-04-23

  A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, β-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.
• [EN] BIODEGRADABLE DRUG-POLYMER CONJUGATE<br/>[FR] CONJUGUÉ MÉDICAMENT-POLYMÈRE BIODÉGRADABLE
  申请人：POLYACTIVA PTY LTD

  公开号：WO2018165711A1

  公开（公告）日：2018-09-20

  A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, β-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.